NEW YORK (GenomeWeb News) – Sequenom has appointed Beckman Coulter CFO and Senior VP of Finance Charles Slacik to serve on its board of directors. Slacik formerly was executive VP and CFO at Watson Pharmaceuticals and senior VP and CFO at the medical technologies company C.R. Bard. Sequenom said in a US Securities and Exchange Commission filing this week that it has granted Slacik a non-qualified stock option to buy 40,000 shares of the company's common stock at $7.89 per share, the market valuation at the date of the grant, and will provide him with additional compensation.
Beckman Coulter disclosed last week that Slacik's employment with the firm will end once its acquisition by Danaher is completed.
Judith Greenberg has been named acting director of the National Institute of General Medical Sciences to temporarily replace departing Director Jeremy Berg. Greenberg is a developmental biologist and has been director of the NIGMS Division of Genetics and Development Biology, which had a budget last year of $566 million, since 1988.
Xceleron said this week that David Roblin has been appointed to its board of directors in a non-executive capacity, and Stuart Best has joined the company as senior director of operations. Roblin most recently was a senior VP of R&D at Pfizer Global R&D. Best formerly was head of bioanalysis at Merck.
Corning has hired Richard Eglen to be VP and GM of its Corning Life Sciences business segment. Eglen formerly led the Bio-discovery business for PerkinElmer. He takes over the post from Senior VP Mark Beck, who has switched over to lead the Corning Environmental Technologies segment.
Olink Bioscience has appointed Simon Frederiksson to be executive VP. Frederickson was one of the founding scientists at Olink as a developer of its Duolink and Proseek platforms, and he has been increasingly involved in the company's business development and research collaboration activities.
The Luxembourg Centre for Systems Biomedicine at the University of Luxembourg has hired Reinhard Schneider from the European Molecular Biology Laboratory to lead its central bioinformatics core.
Synthetic Genomics said this week that Joseph Mahler will join the company as chief financial officer, where he will report to company Founder and CEO J. Craig Venter. Mahler formerly was CFO and a senior executive at FuelCell Energy and he served as a VP and CFO for EarthGro.
Biomarker validation and discovery company Abcodia has appointed Wendy Alderton to be its director of science. Alderton has worked in oncology, neuroscience, inflammation, and project management for several firms including GlaxoSmithkline, Millennium Pharmaceuticals, Piramed, and Summit.
Allegro Diagnostics has appointed Michael Webb to be president and CEO and to serve on its board of directors. Webb previously was president and CEO of Anchor Therapeutics and EPIX Pharmaceuticals. He also is executive chairman of Virtify and he has been chairman of the Massachusetts Biotechnology Council.
Former Enzo Clinical Labs President Kevin Krenitsky has taken over the chief operating officer post at Foundation Medicine, where he will lead the company's internal operations and commercialization plans for its comprehensive cancer diagnostic test. Before his time at Enzo, Krenitsky was CEO at BioServe Biotechnologies and at Parkway Clinical Laboratories.
David Haussler, a professor of biomolecular engineering at the University of California, Santa Cruz, has been awarded the 2011 Weldon Memorial Prize by the University of Oxford. The prize is awarded for contributions to the development of mathematical or statistical methods to be applied to problems in biology.
Hausler is director of the California Institute for Qualitative Biosciences, and he and his team's work has focused on using bioinformatics to understand the human genome, for example by analyzing data from the Cancer Genome Atlas, developing the Cancer Genomics Browser, and by founding the Genome 10K project. The Haussler lab has made discoveries about the existence of ultraconserved elements in the human genome, developing methods for analyzing DNA, RNA, and protein sequences, and demonstrating that retrotransposons have been co-opted into vertebrate genomes.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.